Evidence of NI-0101 pharmacological activity, an anti-TLR4 antibody, in a randomized phase I dose escalation study in healthy volunteers receiving LPS

Therapeutic Options After Treatment Failure in Rheumatoid Arthritis or Spondyloarthritides

(2014) Marcello Govoni et al.   ADVANCES IN THERAPY

A randomized phase 1 pharmacokinetic trial comparing the potential biosimilar PF-05280014 with trastuzumab in healthy volunteers (REFLECTIONS B327-01)

(2014) Donghua Yin et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Phase I, Healthy Subjects Study of Intravenous OPN-305, a Humanized Anti-TLR2 Antibody

(2013) M Reilly et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Cytoplasmic LPS Activates Caspase-11: Implications in TLR4-Independent Endotoxic Shock

(2013) J. A. Hagar et al.   SCIENCE

Noncanonical Inflammasome Activation by Intracellular LPS Independent of TLR4

(2013) N. Kayagaki et al.   SCIENCE

Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor- , in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study

(2011) G. R. Burmester et al.   ANNALS OF THE RHEUMATIC DISEASES

Use of Biologics in Rheumatoid Arthritis: Current and Emerging Paradigms of Care

(2011) Jeffrey R. Curtis et al.   CLINICAL THERAPEUTICS

Eritoran tetrasodium (E5564) treatment for sepsis: review of preclinical and clinical studies

(2011) Amisha Barochia et al.   Expert Opinion on Drug Metabolism & Toxicology

Immune complexes containing citrullinated fibrinogen costimulate macrophages via Toll-like receptor 4 and Fcγ receptor

(2010) Jeremy Sokolove et al.   ARTHRITIS AND RHEUMATISM

A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis*

(2010) Todd W. Rice et al.   CRITICAL CARE MEDICINE

Pharmacokinetics and Antibody Responses to the CD3 Antibody Otelixizumab Used in the Treatment of Type 1 Diabetes

(2010) Geoff Hale et al.   JOURNAL OF CLINICAL PHARMACOLOGY

The Inhibitory Fc IIb Receptor Dampens TLR4-Mediated Immune Responses and Is Selectively Up-regulated on Dendritic Cells from Rheumatoid Arthritis Patients with Quiescent Disease

(2009) M. H. Wenink et al.   JOURNAL OF IMMUNOLOGY

Rheumatoid arthritis

(2009) Lars Klareskog et al.   LANCET

Therapeutic Targeting of Toll-Like Receptors for Infectious and Inflammatory Diseases and Cancer

(2009) L. A. J. O'Neill et al.   PHARMACOLOGICAL REVIEWS

Induction of macrophage secretion of tumor necrosis factor α through Fcγ receptor IIa engagement by rheumatoid arthritis–specific autoantibodies to citrullinated proteins complexed with fibrinogen

(2008) Cyril Clavel et al.   ARTHRITIS AND RHEUMATISM

Circulating immune complexes contain citrullinated fibrinogen in rheumatoid arthritis

(2008) Xiaoyan Zhao et al.   ARTHRITIS RESEARCH & THERAPY